Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Best Infectious Disease News Delivered Weekly

The Contagion® Skin & Soft Tissues Diseases specialty page provides skin & soft tissue-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

SKIN & SOFT TISSUE DISEASES VIDEOS - Page 1

Oral Antibiotic Compliance for ABSSSI
Panelists emphasize the importance of patient education, patient compliance, oral antibiotic adherence, and managing expectations of prescriptions for acute bacterial skin and skin structure infections.
Who is Not a Good Candidate for MRSA Prodrug TXA709?
Daniel Pilch, PhD, explains which patients would not make good candidates for MRSA prodrug TXA709.
Why Was a Specific Meningococcal Disease Vaccine Recommended for the 2016 Rutgers Outbreak?
The CDC offers insight into why a rare exception to the general recommendation of either brand of MenB vaccine had been made for the Rutgers outbreak in 2016.
How Does Zika Differ from Other Congenital Infections?
David A. Schwartz, MD, MS Hyg, FCAP, clinical professor of pathology at Medical College of Georgia, Augusta University, explains how congenital infection with Zika virus differs from congenital infection with other viruses.
Examining the Bactericidal Behavior of a New MRSA Treatment
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains the bactericidal behavior of TXA709, a new drug to treat MRSA infections.
How Does TXA709 Target MRSA?
Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, explains how TXA709 targets MRSA differently than other antibiotics.
How Effective is TXA709 Against MRSA?
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains why MRSA is especially dangerous, and the effectiveness of the team’s new drug, TXA079.
Assessing the Clinical Wellbeing of SSTI Patients
Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, explains how his research can assess clinical well-being of patients with skin and soft tissue infections.
FEATURED
Big advances in treatment can